|Mr. Mark J. Enyedy||Pres, CEO & Director||1.2M||N/A||1964|
|Dr. Thomas Ryll||Sr. VP of Technical Operations||526.23k||N/A||1961|
|Dr. Anna Berkenblit||Sr. VP & Chief Medical Officer||602.68k||N/A||1970|
|Ms. Susan Altschuller Ph.D.||Sr. VP & CFO||N/A||N/A||N/A|
|Mr. David G. Foster||VP of Fin. & Chief Accounting Officer||N/A||N/A||N/A|
|Ms. Courtney O'Konek||Sr. Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Audrey Bergan||VP & Chief HR Officer||N/A||N/A||N/A|
|Dr. Theresa G. Wingrove||Sr. VP of Regulatory Affairs & Quality||N/A||N/A||1958|
|Ms. Stacy A. Coen||Sr. VP & Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Joseph J. Kenny||Sec.||N/A||N/A||N/A|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc.’s ISS Governance QualityScore as of November 2, 2019 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 6.